Human cysticercosis: parasitology, pathology, clinical manifestations and available treatment.
Human cysticercosis is a global health problem and neurocysticercosis a serious clinical syndrome. The diagnosis of neurocysticercosis can now be made with a high degree of accuracy by scrutiny of clinical signs and symptoms in combination with X-ray, computed tomography or magnetic resonance imaging, serological tests and laboratory examinations. Differential clinical diagnosis with tumor, and vascular and inflammatory conditions, may however, prove difficult in nonendemic areas. The management of cysticercosis has been radically changed by the advent of effective chemotherapy. Both the heterocyclic pyrazinoisoquinoline compound, praziquantel and the benzimidazole carbamate, albendazole, have now been extensively tested and successfully used for treatments of neurocysticercosis, usually in combination with corticosteroids. The definition of appropriate criteria and guidelines for the use of chemotherapy, may however, require further research. Surgical interventions continue to play an important role in certain clinical presentations. Recent advances in immunological research hold realistic promise for the development of a vaccine against Taenia solium.
Department of Medical Parasitology, London School of Hygiene and Tropical Medicine, U.K.
G
G
Webbe
D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D003551:Cysticercosis / Q000209:etiology / Q000469:parasitology* / Q000473:pathology / Q000628:therapy; D006790:Host-Parasite Interactions; D006801:Humans; D013621:Taenia / Q000254:growth & development
D000981:Antiprotozoal Agents